Bal-Pharma Stock/Share Prices, Buy and Sell Bal-Pharma NSE Stocks

Market Snapshot

BSE Sensex: 48544.06 1.38%
BSE 500: 19402.96 1.37%
BSE 200: 6220.76 1.38%
BSE 100: 14686.22 1.41%
BSE Mid-Cap: 19943.99 1.46%
BSE Small-Cap: 20805.48 1.21%
BANKEX: 36088.53 3.20%
BSE IT Sector: 26743.1 -2.63%
Nifty 50: 14504.8 1.36%
Nifty 500: 12186.7 1.35%
Nifty 200: 7588.2 1.36%
Nifty 100: 14639.4 1.31%
Nifty Midcap 100: 23516.85 1.74%
Nifty Small 100: 8186.25 1.26%
Nifty IT: 25851.3 -3.28%
Nifty PSU Bank: 2077.65 4.49%

News:

JSW Steel completes acquisitio...
Adani Enterprises unit incorpo...
S&P 500 closes at record high...
Moodys reaffirms Motherson Sum...
Acuit Ratings upgrades credit ...

Bal Pharma Ltd NSE / BSE
Pharmaceuticals, Small Cap

Invest

13 Apr 2021 | 04:14 PM

63.15

0.55 (0.88%)

Add to Watchlist

This awesome feature is still in our labs.
Set Alert

This awesome feature is still in our labs.

Underperforms Index

25.3%

Return (1Y)

Underperformed Nifty 50 by 35.98%
More Volatile

3.89%

Standard Deviation (1Y)

Higher than Nifty 50 by 2.59%
Not so consistent

6/12

Months

underperformed Nifty 50
AxisDirect View

No View

52 Week High-Low

News & Announcements

Board of Bal Pharma allots 6.50 lakh equity shares to promoter
27 days ago

Board of Bal Pharma allots 6.50 lakh equity shares to promoter

17 - Mar - 2021 12:00 AM | 27 days ago

The Board of Bal Pharma has allotted 6.50 lakh equity shares on preferential basis to promoter.
With this allotment, the paid up equity share capital of the Company has risen to Rs.14,82,23,720/- divided into 1,48,22,372 equity shares of Rs.10 each.
Powered by Capital Market - Live News
Bal Pharma receives revision in credit ratings from ICRA
29 days ago

Bal Pharma receives revision in credit ratings from ICRA

15 - Mar - 2021 12:00 AM | 29 days ago

Bal Pharma has received upgrade in credit ratings from ICRA as under -
Long term fund based facilities - ICRA BB reaffirmed; Outlook revised to Stable from Negative.
Short term fund non fund based facilities - ICRA A4 reaffirmed
Long term - term loan - ICRA BB; Outlook revised to Stable from Negative.
Powered by Capital Market - Live News
Bal Pharma to conduct board meeting
35 days ago

Bal Pharma to conduct board meeting

09 - Mar - 2021 12:00 AM | 35 days ago

Bal Pharma will hold a meeting of the Board of Directors of the Company on 17 March 2021.
Powered by Capital Market - Live News
Bal Pharma reports consolidated net profit of Rs 0.32 crore in the December 2020 quarter
58 days ago

Bal Pharma reports consolidated net profit of Rs 0.32 crore in the December 2020 quarter

15 - Feb - 2021 12:00 AM | 58 days ago

Net profit of Bal Pharma reported to Rs 0.32 crore in the quarter ended December 2020 as against net loss of Rs 3.57 crore during the previous quarter ended December 2019. Sales rose 46.00% to Rs 63.03 crore in the quarter ended December 2020 as against Rs 43.17 crore during the previous quarter ended December 2019.
Particulars Quarter Ended
Dec. 2020 Dec. 2019 % Var.
Sales 63.03 43.17 46
OPM % 9.41 1.62 -
PBDT 3.23 -1.69 LP
PBT 1.20 -3.11 LP
NP 0.32 -3.57 LP
Powered by Capital Market - Live News

Price vs Volume

Stock Trivia

MF shareholding in Bal Pharma Ltd has decreased by -100% since past 3 Months
MF shareholding in Bal Pharma Ltd has decreased by -100% since past 1 Year

Peer Comparison on Risk - Return

Thanks for Liking, Please spread your love by sharing...

Particulars	Quarter Ended
	Dec. 2020	Dec. 2019	% Var.
Sales	63.03	43.17	46
OPM %	9.41	1.62	-
PBDT	3.23	-1.69	LP
PBT	1.20	-3.11	LP
NP	0.32	-3.57	LP

General Notifications

My Notifications

Research Notifications

Bal Pharma Ltd NSE / BSE Pharmaceuticals, Small Cap

63.15 0.55 (0.88%)

News & Announcements

Price vs Volume

Stock Trivia

Bal Pharma Ltd NSE / BSE
Pharmaceuticals, Small Cap

63.15

0.55 (0.88%)